Acorda Therapeutics was founded in 1995 and is headquartered in Ardsley, US

Acorda Therapeutics has offices in Ardsley, Chelsea, South San Francisco and Waltham

Ardsley, US (HQ)

420 Saw Mill River Rd

Waltham, US

283 Bear Hill Rd

South San Francisco, US

701 Gateway Blvd

Chelsea, US

190 Everett Ave

Acorda Therapeutics's revenue was reported to be $119.4 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 119.4 m |

## Gross profit (Q1, 2017) | 94.2 m |

## Gross profit margin (Q1, 2017), % | 79% |

## Net income (Q1, 2017) | (18.9 m) |

## EBIT (Q1, 2017) | (15.3 m) |

## Market capitalization (15-Aug-2017) | 974 m |

## Cash (31-Mar-2017) | 133.6 m |

Acorda Therapeutics's current market capitalization is $974 m.

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 336.4 m | 401.5 m | 492.7 m | 519.6 m |

## Revenue growth, % | 19% | 23% | 5% | |

## Cost of goods sold | 66 m | 80 m | 92.3 m | 107.5 m |

## Gross profit | 270.4 m | 321.5 m | 400.4 m | 412.1 m |

## Gross profit Margin, % | 80% | 80% | 81% | 79% |

## R&D expense | 53.9 m | 73.5 m | 149.2 m | 203.4 m |

## General and administrative expense | 185.5 m | 201.8 m | 205.6 m | 235.4 m |

## Operating expense total | 306.1 m | 365.1 m | 458.7 m | 555.6 m |

## EBIT | 30.4 m | 36.4 m | 34 m | (36 m) |

## EBIT margin, % | 9% | 9% | 7% | (7%) |

## Interest expense | (2.2 m) | (9.3 m) | (15.5 m) | (16.5 m) |

## Interest income | 668 k | 674 k | 440 k | 339 k |

## Pre tax profit | 28.9 m | 28 m | 19.4 m | (42.3 m) |

## Income tax expense | (8.3 m) | 6.7 m | ||

## Net Income | 16.4 m | 17.7 m | 11.1 m | (35.6 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 97.1 m | 106 m | 99.9 m | 113.7 m | 148.2 m | 115.9 m | 127.5 m | 135.6 m | 119.4 m |

## Cost of goods sold | 18.9 m | 20.6 m | 18.4 m | 22.7 m | 24.7 m | 23.2 m | 26.4 m | 27.6 m | 25.2 m |

## Gross profit | 78.2 m | 85.4 m | 81.4 m | 91 m | 123.5 m | 92.7 m | 101 m | 108 m | 94.2 m |

## Gross profit Margin, % | 81% | 81% | 82% | 80% | 83% | 80% | 79% | 80% | 79% |

## R&D expense | 16.4 m | 16.6 m | 30.6 m | 31.2 m | 43.4 m | 44.6 m | 50.3 m | 54.8 m | 46.5 m |

## General and administrative expense | 50.6 m | 47.8 m | 48.8 m | 52.8 m | 51.1 m | 59 m | 62.6 m | 54.8 m | 52 m |

## Operating expense total | 67.1 m | 64.4 m | 79.4 m | 84 m | 94.4 m | 103.6 m | 112.9 m | 109.6 m | 98.5 m |

## EBIT | 11 m | 20.8 m | (1.3 m) | 5.7 m | 25.7 m | (17.2 m) | (14 m) | (5.5 m) | (15.3 m) |

## EBIT margin, % | 11% | 20% | (1%) | 5% | 17% | (15%) | (11%) | (4%) | (13%) |

## Interest expense | (426 k) | (4.6 m) | (4.1 m) | (4 m) | (4 m) | (3.7 m) | (4 m) | (4.4 m) | (4.1 m) |

## Interest income | 165 k | 257 k | 66 k | 94 k | 120 k | 215 k | 48 k | 46 k | 38 k |

## Pre tax profit | 10.7 m | 16.5 m | (5.1 m) | 21.7 m | (19.9 m) | (10 m) | |||

## Income tax expense | (6 m) | (4.5 m) | (17.8 m) | 972 k | |||||

## Net Income | 5.4 m | 17.3 m | (3.1 m) | (2.1 m) | 1.9 m | (520 k) | (19.5 m) | (32.5 m) | (18.9 m) |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 48 m | 182.2 m | 153.2 m | 158.5 m |

## Accounts Receivable | 1 m | 71.3 m | ||

## Inventories | 43.1 m | |||

## Current Assets | 367.3 m | 409.1 m | 451.3 m | 272.7 m |

## PP&E | 16.5 m | 46.1 m | 40.2 m | 34.3 m |

## Goodwill | 183 m | 183.6 m | 280.6 m | |

## Total Assets | 607.1 m | 1.1 b | 1.1 b | 1.3 b |

## Accounts Payable | 15.9 m | 17.8 m | 14.2 m | 26.9 m |

## Total Debt | 331.1 m | |||

## Current Liabilities | 96.6 m | 114.4 m | 90.6 m | 147.9 m |

## Common Stock | 46 k | |||

## Additional Paid-in Capital | 678.7 m | 761 m | 812.8 m | 921.4 m |

## Retained Earnings | (238.1 m) | (220.4 m) | (209.4 m) | (244 m) |

## Total Equity | 440.4 m | 540.3 m | 603 m | 664.2 m |

## Debt to Equity Ratio | 0.5 x | |||

## Debt to Assets Ratio | 0.2 x | |||

## Financial Leverage | 1.4 x | 2 x | 1.9 x | 2 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 274.6 m | 53.3 m | 61.5 m | 76.2 m | 89.8 m | 431.4 m | 137.4 m | 127.9 m | 133.6 m |

## Inventories | 30.8 m | 26.6 m | 45.3 m | 48.6 m | 46.8 m | ||||

## Current Assets | 693.1 m | 843.9 m | 423.8 m | 427.6 m | 429.6 m | 544.3 m | 263.2 m | 238 m | 248.2 m |

## PP&E | 15.8 m | 17.1 m | 45.9 m | 44.5 m | 42.4 m | 38 m | 36.8 m | 35.8 m | 37.1 m |

## Goodwill | 183 m | 183 m | 183.6 m | 183.6 m | 284.5 m | 284 m | 278.1 m | ||

## Total Assets | 943.3 m | 972.8 m | 1.1 b | 1.1 b | 1.1 b | 1.2 b | 1.3 b | 1.3 b | 1.3 b |

## Accounts Payable | 20.7 m | 20.5 m | 21.9 m | 16.9 m | 14 m | 21.4 m | 29.6 m | 18.6 m | 21.4 m |

## Current Liabilities | 94.6 m | 100.9 m | 122.2 m | 111.7 m | 93.2 m | 105 m | 136.1 m | 118.1 m | 119.3 m |

## Additional Paid-in Capital | 733.3 m | 743.8 m | 772.9 m | 783.1 m | 793.8 m | 894.2 m | 904.8 m | 911.5 m | 937.7 m |

## Retained Earnings | (232.7 m) | (220.7 m) | (223.5 m) | (222.5 m) | (218.6 m) | (209.9 m) | (228.2 m) | (240.9 m) | (250.8 m) |

## Total Equity | 500.4 m | 522.9 m | 549 m | 560.3 m | 574.9 m | 684 m | 681.5 m | 666.8 m | 676.1 m |

## Financial Leverage | 1.9 x | 1.9 x | 2 x | 2 x | 1.9 x | 1.8 x | 2 x | 2 x | 2 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | 16.4 m | 17.7 m | 11.1 m | (35.6 m) |

## Depreciation and Amortization | 7 m | 8.5 m | 15 m | 21.6 m |

## Accounts Receivable | (4.5 m) | (1.4 m) | 744 k | (20 m) |

## Inventories | (10.2 m) | (6.7 m) | ||

## Accounts Payable | 59.9 k | 59.9 k | 37.6 m | |

## Cash From Operating Activities | 6.2 m | 134.1 m | (29 m) | 35.3 m |

## Purchases of PP&E | (4 m) | (5.1 m) | (5.9 m) | (6.2 m) |

## Cash From Investing Activities | (45.1 m) | (293.8 m) | (85.2 m) | (73.8 m) |

## Cash From Financing Activities | 12 m | 352.9 m | 17.8 m | 45.9 m |

## Interest Paid | 2 m | 4.5 m | 7.2 m | 6.1 m |

## Income Taxes Paid | 2.6 m | 4.4 m | 4.7 m | 4.3 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | 5.4 m | 17.3 m | (3.1 m) | (2.1 m) | 1.9 m | (520 k) | (19.5 m) | (32.5 m) | (18.9 m) |

## Depreciation and Amortization | 3.6 m | 5.4 m | 3.7 m | 7.5 m | 11.2 m | 3.9 m | 9.9 m | 15.8 m | 5.6 m |

## Accounts Receivable | 3.8 m | 6 m | 1.7 m | 2.4 m | 455 k | (10.2 m) | (14.3 m) | (17 m) | 2 m |

## Inventories | (5.3 m) | (1.1 m) | (19 m) | (22.4 m) | (20.6 m) | ||||

## Cash From Operating Activities | 23 m | 61.4 m | (9.3 m) | (6 m) | 16.2 m | 6.7 m | (2.9 m) | 2.9 m | (25.4 m) |

## Purchases of PP&E | (1.4 m) | (2.3 m) | (2.6 m) | (4.1 m) | (5 m) | (1 m) | (2.5 m) | (4.6 m) | (5.8 m) |

## Cash From Investing Activities | (138 m) | (400.8 m) | (116 m) | (106.1 m) | (116.3 m) | 198.3 m | (71.2 m) | (73.5 m) | (5.8 m) |

## Cash From Financing Activities | 341.6 m | 344.7 m | 4.6 m | 6.1 m | 7.8 m | 73.2 m | 58 m | 45.1 m | 6 m |

## Interest Paid | 706 k | 1.2 m | 463 k | 4 m | 4.3 m | 21 k | 3 m | 3 m | 29 k |

## Income Taxes Paid | 1.2 m | 1.8 m | 743 k | 1.3 m | 2.2 m | 157 k | 2.6 m | 3.6 m | 1.9 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 200 k |

## Financial Leverage | 2 x |